Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity

CompletedOBSERVATIONAL
Enrollment

255

Participants

Timeline

Start Date

November 8, 2019

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Type 2 DiabetesObesityCannabis UseInsulin Sensitivity
Interventions
OTHER

Study A: Single use of cannabis flower product

Participants are asked to purchase and use one of three cannabis flower strains with differing levels of THC and CBD: 1) CBD (\~14% CBD/0% THC), 2) THC (\~14% THC/0% CBD), or 3) THC+CBD (\~7% THC/7% CBD).

OTHER

Study B: Ad libitum cannabis use for four weeks or no cannabis use

Participants choose whether to use a cannabis flower product ad libitum for four weeks or to not use cannabis for four weeks. Participants who choose to use cannabis are asked to purchase and use one of three cannabis flower strains with differing levels of THC and CBD: 1) CBD (\~14% CBD/0% THC), 2) THC (\~14% THC/0% CBD), or 3) THC+CBD (\~7% THC/7% CBD).

Trial Locations (1)

80301

Center for Innovation and Creativity, Boulder

All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

lead

University of Colorado, Boulder

OTHER

NCT04114903 - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity | Biotech Hunter | Biotech Hunter